• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

    3/24/25 7:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LXEO alert in real time by email

    Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI across participants with abnormal LVMI at baseline, frataxin expression to be evaluated for any increase from baseline rather than numerical threshold

    Interim update from cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial: observed 71% and 115% increases in PKP2 protein expression in first two post-treatment biopsies; first participant evaluated 6-months after dosing experienced 67% reduction in premature ventricular contractions (PVCs)

    Completed enrollment of cohort 2 of LX2020 HEROIC-PKP2 Phase 1/2 trial; interim clinical data update expected in second half of 2025

    LX2020 has been generally well tolerated with no treatment-related serious adverse events to date

    Cash, cash equivalents and investments of $128.5 million expected to provide operational runway into 2027

    NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today provided business updates across its portfolio and reported fourth quarter and full year 2024 financial results.

    "We are pleased to share further regulatory clarity for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, and we appreciate the continued partnership from the FDA on an accelerated approval pathway to support adults and children living with this devastating condition," said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. "We are also encouraged by the favorable safety profile and early data observed in participants dosed with LX2020 to date. We look forward to sharing additional clinical updates later in 2025 now that the second cohort of the LX2020 HEROIC-PKP2 Phase 1/2 trial in arrhythmogenic cardiomyopathy is fully enrolled."

    Business and Program Updates

    LX2006 for the Treatment of FA Cardiomyopathy:

    • Regulatory Update: Further alignment on elements of the accelerated development pathway following a Type B RMAT meeting with the U.S. Food and Drug Administration (FDA):
      • Frataxin expression to be evaluated for any increase from baseline rather than numerical threshold, based on improvements to date in LVMI across participants with abnormal LVMI at baseline
      • Inclusion of pediatric cohorts, both adolescents and children, in planned pivotal study
      • Use of prospective natural history data as external control in planned pivotal study
      • Final dose selection and remaining elements of registrational trial alignment expected in 2025

    In light of these regulatory updates and anticipated timelines for assay validation, the Company expects to measure frataxin protein expression using liquid chromatography mass spectrometry (LCMS) in the planned registrational trial.

    • Mid-Year Clinical Update Expected to Include:
      • Safety and tolerability data for all participants dosed across both the SUNRISE-FA and Weill Cornell clinical trials (at least 16 participants, including 6 participants with abnormal LVMI at baseline)
      • Pre- and post-treatment cardiac frataxin protein expression measured via LCMS for all four participants at the highest dose (1.2x1012 vg/kg, Cohort 3)
      • Clinical biomarker data, including left ventricular mass index (LVMI), left ventricular wall thickness and high-sensitivity troponin I, for participants with >6-months of follow up
      • Functional and patient-reported outcome data for participants with >6-months of follow up
    • Safety: LX2006 continues to be generally well tolerated with no new treatment-related serious adverse events to report

    LX2020 for the Treatment of PKP2-ACM:

    • Cohort 1 Interim Update: Post-treatment cardiac biopsies from two participants in cohort 1 showed increases in PKP2 protein expression from baseline; the third cohort 1 participant elected not to undergo a post-treatment biopsy
      • Observed increases in exogenous mRNA and 71% and 115% increases in PKP2 protein levels from baseline
      • First participant evaluated 6-months post treatment experienced 67% reduction in PVCs from baseline (from 861 to 284) and resolution of non-specific intraventricular block (normalization of QRS duration)
    • Enrollment Update: Completed enrollment of cohort 2 of LX2020 HEROIC-PKP2 (n=3), interim clinical data update expected in second half of 2025
    • Safety: LX2020 has been generally well tolerated with no treatment-related serious adverse events to date across both dose cohorts
    • Regulatory Update: In March 2025 the European Commission granted orphan medicinal product designation for LX2020 for the treatment of PKP2-ACM

    Fourth Quarter and Full Year Financial Results

    • Cash Position: As of December 31, 2024, cash, cash equivalents, and investments were $128.5 million, which Lexeo believes will be sufficient to fund operations into 2027.
    • R&D Expenses: R&D expenses were $18.4 million for the three months ended December 31, 2024, compared to $8.2 million for the three months ended December 31, 2023. R&D expenses were $74.1 million for the year ended December 31, 2024, compared to $53.1 million for the year ended December 31, 2023.
    • G&A Expenses: G&A expenses were $9.0 million for the three months ended December 31, 2024, compared to $6.8 million for the three months ended December 31, 2023. G&A expenses were $31.7 million for the year ended December 31, 2024, compared to $15.4 million for the year ended December 31, 2023.
    • Net Loss: Net loss was $25.9 million or $0.78 per share (basic and diluted) for the three months ended December 31, 2024, compared to $14.2 million or $0.86 per share (basic and diluted) for the three months ended December 31, 2023. Net loss was $98.3 million or $3.09 per share (basic and diluted) for the year ended December 31, 2024, compared to $66.4 million or $12.40 per share (basic and diluted) for the year ended December 31, 2023.

    About Lexeo Therapeutics

    Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, LX2020 for the treatment of plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and other devastating diseases with high unmet need.

    Cautionary Note Regarding Forward-Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Lexeo's expectations and plans regarding its current product candidates and programs and the timing for receipt and announcement of data from its clinical trials, the timing and likelihood of potential regulatory approval, and expectations regarding the time period over which Lexeo's capital resources will be sufficient to fund its anticipated operations and estimates regarding Lexeo's financial condition. Words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo's filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company's control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: risks and uncertainties related to global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of Lexeo's preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo's Annual Report on Form 10-K for the annual period ended December 31, 2023, filed with the SEC on March 11, 2024, Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the SEC on November 13, 2024, and subsequent future filings Lexeo may make with the SEC. Additional information will also be set forth in Lexeo's Annual Report on Form 10-K for the year ended December 31, 2024. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

    Media Response:

    [email protected]

    Investor Response:

    Carlo Tanzi, Ph.D.

    [email protected]



    Lexeo Therapeutics, Inc.

    Selected Financial Information

    (in thousands, except share and per share amounts)

    Statements of Operations

     Three Months Ended December 31,  Year Ended December 31, 
     2024  2023  2024  2023 
     (unaudited)  (unaudited)       
    Operating expenses           
    Research and development$18,366  $8,210  $74,091  $53,130 
    General and administrative 9,016   6,764   31,675   15,383 
    Total operating expenses 27,382   14,974   105,766   68,513 
    Operating loss (27,382)  (14,974)  (105,766)  (68,513)
    Other income and expense           
    Loss on fair value adjustment to convertible SAFE Note -   (258)  -   (530)
    Other income (expense), net -   (8)  (9)  (13)
    Interest expense (30)  (51)  (137)  (205)
    Interest income 1,465   1,103   7,556   2,867 
    Accretion of discount on investments 23   -   23   - 
    Total other income and expense 1,458   786   7,433   2,119 
    Loss from operations before income taxes (25,924)  (14,188)  (98,333)  (66,394)
    Income taxes -   -   -   - 
    Net loss$(25,924) $(14,188) $(98,333) $(66,394)
    Net loss per common share, basic and diluted$(0.78) $(0.86) $(3.09) $(12.40)
    Weighted average number of shares outstanding used in computation of net loss per common share, basic and diluted 33,076,094   16,438,237   31,787,491   5,354,368 



    Balance Sheet Data

      December 31,  December 31, 
      2024  2023 
    Cash, cash equivalents, and investments $128,530  $121,466 
    Total assets  146,942   139,807 
    Total liabilities  30,100   26,272 
    Total stockholders' equity  116,842   113,535 


    Primary Logo

    Get the next $LXEO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LXEO

    DatePrice TargetRatingAnalyst
    6/13/2024$28.00Outperform
    Robert W. Baird
    6/6/2024$22.00Buy
    H.C. Wainwright
    11/28/2023$20.00Overweight
    JP Morgan
    11/28/2023$20.00Buy
    Stifel
    11/28/2023$19.00Outperform
    Leerink Partners
    11/28/2023$22.00Outperform
    RBC Capital Mkts
    11/28/2023$23.00Buy
    Chardan Capital Markets
    More analyst ratings

    $LXEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cholmondeley Paula H bought $104,852 worth of shares (15,000 units at $6.99), increasing direct ownership by 96% to 30,627 units (SEC Form 4)

      4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

      11/26/24 5:00:06 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    SEC Filings

    See more
    • Lexeo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)

      5/27/25 7:32:57 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

      SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

      5/15/25 9:58:26 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

      SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

      5/14/25 12:00:47 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Financials

    Live finance-specific insights

    See more

    $LXEO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $LXEO
    Leadership Updates

    Live Leadership Updates

    See more
    • Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

      Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of participants LX1001 well tolerated across all dose cohorts with no reports of amyloid-related imaging abnormalities (ARIA) Company to host webcast today at 7:00 AM ET NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced positive interim results from the Phase 1/2 study of LX1001

      10/30/24 6:14:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

      NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo's ongoing SUNRISE-FA Phase 1/2 clinical

      7/11/24 8:00:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

      Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced it has entered into a securities purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 20,790,120 shares ("Shares") of its common sto

      5/27/25 7:31:10 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

      Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected to begin by early 2026; commencing enrollment in prospective natural history study, CLARITY-FA, in Q2 2025 to serve as concurrent external control Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently enrolling patients in Cohort 3; interim clinical data update on track for second half of 2025 Redeployed $20 million to focus on clinical-stage programs; cash, cash equivalents and investments of $106.9 million expected to prov

      5/12/25 7:00:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

      NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its AAV manufacturing approach will be presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 13-17, 2025 in New Orleans, LA. "The data being presented at ASGCT underscore the strength of our industry-leading capabilities in AAV manufacturing with high yield and high quality," said José Manuel Otero, Chief Technical Officer of Lexeo Therapeutics. "Scientists at Lexeo have optimized a manufacturing platfo

      5/1/25 9:16:04 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

      NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs. "Kyle has an exceptional track record as an operator and life sciences portfolio manager, and we are excited to welcome him to Lexeo at a time when we are advancing our pipeline and tran

      12/19/24 7:00:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

      Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/

      11/13/24 7:30:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

      Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 Cash and cash equivalents of $175.0 million expected to provide operational runway into 2027 NEW YORK, Aug. 12, 2024 (GLOBE N

      8/12/24 7:00:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Lexeo Therapeutics with a new price target

      Robert W. Baird initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $28.00

      6/13/24 7:10:25 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Lexeo Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $22.00

      6/6/24 7:17:54 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan initiated coverage on Lexeo Therapeutics with a new price target

      JP Morgan initiated coverage of Lexeo Therapeutics with a rating of Overweight and set a new price target of $20.00

      11/28/23 7:29:52 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

      SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

      11/14/24 5:49:30 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

      SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

      11/14/24 4:45:58 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

      SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

      11/14/24 12:32:15 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Adler Eric sold $1,623 worth of shares (585 units at $2.77), decreasing direct ownership by 0.86% to 67,681 units (SEC Form 4)

      4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

      5/20/25 5:00:14 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Legal Officer Robertson Jenny sold $1,445 worth of shares (521 units at $2.77), decreasing direct ownership by 0.82% to 63,098 units (SEC Form 4)

      4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

      5/20/25 5:00:12 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Townsend Richard Nolan sold $2,979 worth of shares (1,074 units at $2.77), decreasing direct ownership by 0.48% to 221,173 units (SEC Form 4)

      4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

      5/20/25 5:00:15 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care